304 related articles for article (PubMed ID: 32371863)
21. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
[TBL] [Abstract][Full Text] [Related]
22. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
Dunham D; Viswanathan P; Gill J; Manzano M
J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
[TBL] [Abstract][Full Text] [Related]
23. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.
Shah K; Al Ashiri L; Nasimian A; Ahmed M; Kazi JU
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902436
[TBL] [Abstract][Full Text] [Related]
25. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
26. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
27. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
[TBL] [Abstract][Full Text] [Related]
28. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
29. Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Sale MJ; Minihane E; Monks NR; Gilley R; Richards FM; Schifferli KP; Andersen CL; Davies EJ; Vicente MA; Ozono E; Markovets A; Dry JR; Drew L; Flemington V; Proia T; Jodrell DI; Smith PD; Cook SJ
Nat Commun; 2019 Nov; 10(1):5167. PubMed ID: 31727888
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
31. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
32. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
36. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
37. Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
Cell Death Dis; 2014 Feb; 5(2):e1072. PubMed ID: 24556687
[TBL] [Abstract][Full Text] [Related]
38. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
[No Abstract] [Full Text] [Related]
39. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
[TBL] [Abstract][Full Text] [Related]
40. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Gómez-Benito M; Marzo I; Anel A; Naval J
Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]